Compare MEC & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEC | OVID |
|---|---|---|
| Founded | 1945 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 527.1M | 562.5M |
| IPO Year | 2019 | 2017 |
| Metric | MEC | OVID |
|---|---|---|
| Price | $19.11 | $2.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $24.33 | $4.60 |
| AVG Volume (30 Days) | 448.1K | ★ 1.4M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | $10.65 | N/A |
| Revenue Next Year | $8.66 | $19.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $12.25 | $1.12 |
| 52 Week High | $38.76 | $3.11 |
| Indicator | MEC | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 26.26 | 46.31 |
| Support Level | $17.20 | $2.60 |
| Resistance Level | $19.42 | $2.77 |
| Average True Range (ATR) | 0.99 | 0.13 |
| MACD | 0.17 | -0.03 |
| Stochastic Oscillator | 2.39 | 10.29 |
Mayville Engineering Co Inc is involved in a manufacturing partner providing a full suite of manufacturing solutions from concept to production, including design, prototyping and tooling, fabrication, aluminum extrusion, coating, assembly, and aftermarket components. Its customers operate in diverse end markets, including heavy- and medium-duty commercial vehicles, construction, powersports, agriculture, military, and other end markets. Its services comprise stamping, shearing, fiber laser cutting, forming, drilling, tapping, grinding, tube bending, machining, welding, assembly, and logistic services.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.